trending Market Intelligence /marketintelligence/en/news-insights/trending/vzKQBoSy81lmVSwCk_ZRQQ2 content esgSubNav
In This List

Pfizer, Array collaborate to study combination cancer therapies

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfizer, Array collaborate to study combination cancer therapies

Pfizer Inc. and Array BioPharma Inc. entered into a clinical trial collaboration agreement to study the combination of several cancer immunotherapies.

The collaboration includes the study of Array's binimetinib with Pfizer's investigational talazoparib and avelumab. The companies will conduct a phase 1b trial along with a dose-establishing trial.

Initially the focus will be in non-small cell lung cancer and pancreatic cancer, and additional indications will be explored at a later stage. The study is expected to begin by the third quarter of 2018.

Pfizer will sponsor and fund the trial and Array will provide binimetinib supply.

Avelumab, or Bavencio, is jointly developed by Merck KGaA and Pfizer. It was granted accelerated approval by the U.S. Food and Drug Administration for Merkel cell carcinoma and metastatic urothelial carcinoma.